打开APP

Ensemble与诺华联手研究IL-17拮抗新药secukinumab

  1. Ensemble
  2. secukinumab
  3. 诺华

来源:生物谷 2013-08-09 09:47

2013年8月8日讯 /生物谷BIOON/ --就在总部位于麻省的Ensemble医疗公司刚刚解除了与Alexion公司的研究协议后,又传出消息称,公司与诺华公司联手研制一种IL-17拮抗剂新药secukinumab。两家公司都未透露协议中研究的具体计划,但是Ensemble公司的研究人员表示,这次合作主要是开发出secukinumab的口服剂型作为已经完成的注射剂型的补充。

2013年8月8日讯 /生物谷BIOON/ --就在总部位于麻省的Ensemble医疗公司刚刚解除了与Alexion公司的研究协议后,又传出消息称,公司与诺华公司联手研制一种IL-17拮抗剂新药secukinumab。两家公司都未透露协议中研究的具体计划,但是Ensemble公司的研究人员表示,这次合作主要是开发出secukinumab的口服剂型作为已经完成的注射剂型的补充。(生物谷Bioon.com)

详细英文报道:

Just a few weeks after closing a research pact on rare diseases with Alexion ($ALXN), Cambridge, MA-based Ensemble Therapeutics has come away from the deal table with a major league partner for their in-house IL-17 agonist program. Novartis ($NVS) is in-licensing the anti-inflammatory work, Ensemble's most advanced preclinical program, adding another marquee name to the biotech's roster of collaborators.

Novartis always likes to keep its deal terms close to its vest, and it isn't relenting now. The Big Pharma company is paying an undisclosed upfront and a secret lineup of milestones for the work. And the multinational will also fork over research support payments during the collaboration as well. Ensemble has now collected a group of top collaborators which also includes Pfizer ($PFE), Boehringer Ingelheim, Bristol-Myers Squibb ($BMY) and Genentech.

These companies have come calling as Ensemble proselytized its work on mid-sized molecules--"ensemblins"--that are billed to do orally what biologics accomplish only after being injected into a patient. The big idea here is that Ensemble has figured out a new approach to synthetically create an easy-to-take regimen of therapies that have been beyond the reach of the industry. It's primarily focused on elusive protein-protein and protein-peptide interactions, with a big interest in oncology and immuno-inflammatory diseases. And it's still very much early-on in terms of their clinical development work.

The company has been in talks with Novartis regarding the IL-17 program since last fall.

"They're the leaders of the IL-17 field," Ensemble CEO Mike Taylor tells FierceBiotech. "Having the opportunity to partner with them is the best opportunity to maximize the value of the program over the long-term."

Last month Novartis boasted that it's anti-IL-17 treatment, secukinumab, beat out Enbrel in a head-to-head psoriasis study. This new deal with Ensemble offers a complementary oral companion to an injectable Novartis recently tapped as one of 14 leading drug hopefuls in the late-stage pipeline. In addition to psoriasis, Novartis plans to release more late-stage results on secukinumab for arthritic conditions next year. And the pharma giant told investors two years ago that secukinumab was a blockbuster contender, with its first regulatory filing slated for later this year.

"We have a pretty full plate now," says Taylor, who's been able to rely on a steady stream of collaboration cash to operate the company.

 

版权声明 本网站所有注明“来源:生物谷”或“来源:bioon”的文字、图片和音视频资料,版权均属于生物谷网站所有。非经授权,任何媒体、网站或个人不得转载,否则将追究法律责任。取得书面授权转载时,须注明“来源:生物谷”。其它来源的文章系转载文章,本网所有转载文章系出于传递更多信息之目的,转载内容不代表本站立场。不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。

87%用户都在用生物谷APP 随时阅读、评论、分享交流 请扫描二维码下载->